Page 35 - Read Online

Li et al. Hepatoma Res 2020;6:15 I http://dx.doi.org/10.20517/2394-5079.2019.34 Page 13 of 13

128. Guo X, Jiang H, Shi B, Zhou M, Zhang H, et al. Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T
cells against hepatocellular carcinoma. Front Pharmacol 2018;9:1118.
129. Pan Z, Di S, Shi B, Jiang H, Shi Z, et al. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T
cells by coexpression of a soluble PD1-CH3 fusion protein. Cancer Immunol Immunother 2018;67:1621-34.
130. Hu W, Huang X, Huang X, Chen W, Hao L, et al. Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB
promote CAR-T proliferation and tumor rejection. Biomed Pharmacother 2019;118:109333.
131. Chen Y, E CY, Gong ZW, Liu S, Wang ZX, et al. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Hepatobiliary
Pancreat Dis Int 2018;17:301-9.
132. Sun B, Yang D, Dai H, Liu X, Jia R, et al. Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells. Cancer Immunol
Res 2019;7:1813-23.
133. Zhang RY, Wei D, Liu ZK, Yong YL, Wei W, et al. Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for
hepatocellular carcinoma therapy. Front Cell Dev Biol 2019;7:233.
134. Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, et al. Immunotherapy of HCC metastases with autologous T cell receptor
redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62:486-91.
135. Spear TT, Callender GG, Roszkowski JJ, Moxley KM, Simms PE, et al. TCR gene-modified T cells can efficiently treat established
hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immunother 2016;65:293-304.
136. Zhu W, Peng Y, Wang L, Hong Y, Jiang X, et al. Identification of alpha-fetoprotein-specific T-cell receptors for hepatocellular
carcinoma immunotherapy. Hepatology 2018;68:574-89.
137. Spear TT, Evavold BD, Baker BM, Nishimura MI. Understanding TCR affinity, antigen specificity, and cross-reactivity to improve
TCR gene-modified T cells for cancer immunotherapy. Cancer Immunol Immunother 2019;68:1881-9.
138. Tendeiro Rego R, Morris EC, Lowdell MW. T-cell receptor gene-modified cells: past promises, present methodologies and future
challenges. Cytotherapy 2019;21:341-57.
139. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed
with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009;49:124-32.
140. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, et al. A phase I/II trial testing immunization of hepatocellular carcinoma
patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 2006;12:2817-25.
141. Tada F, Abe M, Hirooka M, Ikeda Y, Hiasa Y, et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in
patients with hepatocellular carcinoma. Int J Oncol 2012;41:1601-9.
142. Lee JH, Lee Y, Lee M, Heo MK, Song JS, et al. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic
cells in patients with hepatocellular carcinoma. Br J Cancer 2015;113:1666-76.
143. Lee JH, Tak WY, Lee Y, Heo MK, Song JS, et al. Adjuvant immunotherapy with autologous dendritic cells for hepatocellular
carcinoma, randomized phase II study. Oncoimmunology 2017;6:e1328335.
144. Lu Z, Zuo B, Jing R, Gao X, Rao Q, et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular
carcinoma mouse models. J Hepatol 2017;67:739-48.
145. Pang YB, He J, Cui BY, Xu S, Li XL, et al. A potential antitumor effect of dendritic cells fused with cancer stem cells in hepatocellular
carcinoma. Stem Cells Int 2019;2019:5680327.
146. Kodumudi KN, Siegel J, Weber AM, Scott E, Sarnaik AA, et al. Immune checkpoint blockade to improve tumor infiltrating
lymphocytes for adoptive cell therapy. PloS One 2016;11:e0153053.
147. John LB, Devaud C, Duong CP, Yong CS, Beavis PA, et al. Anti-PD-1 antibody therapy potently enhances the eradication of
established tumors by gene-modified T cells. Clin Cancer Res 2013;19:5636-46.
148. Mahvi DA, Meyers JV, Tatar AJ, Contreras A, Suresh M, et al. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal
melanoma immunity in mice. J Immunother 2015;38:54-61.
149. Jung IY, Lee J. Unleashing the therapeutic potential of CAR-T cell therapy using gene-editing technologies. Mol Cells 2018;41:717-23.
150. Zhang R, Zhang Z, Liu Z, Wei D, Wu X, et al. Adoptive cell transfer therapy for hepatocellular carcinoma. Front Med 2019;13:3-11.